Top Markets
Coin of the day
Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc.

OTLC
Hisse Senetlerindeki Sıralama #30395
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Hisse Fiyatı
$0.03834
Son senkronizasyon: 2026-08-18
Piyasa Değeri
$17.01M
Değişim (1 gün)
-4.15%
Değişim (1 yıl)
-24.82%
Ülke
US
Ticaret Oncotelic Therapeutics, Inc. (OTLC)

Kategori

Oncotelic Therapeutics, Inc. (OTLC) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $0.04 - 2026-08-01

Gün sonu en düşük fiyat: $1.13K - 1993-08-01
Oncotelic Therapeutics, Inc. için hisse fiyatı geçmişi: 1993 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) -32.69%
2025 190.53%
2024 -20.32%
2023 -22.41%
2022 -69.52%
2021 -23.89%
2020 10.12%
2019 94.22%
2018 -42.06%
2017 -52.99%
2016 -55.78%
2015 -50.20%
2014 -33.92%
2013 -46.34%
2012 -62.10%
2011 -75.63%
2010 -81.77%
2009 63.41%
2008 -70.61%
2007 -50.93%
2006 16.57%
2005 -22.97%
2004 -35.60%
2003 628.33%
2002 -57.82%
2001 -63.45%
2000 -53.89%
1999 80.93%
1998 -47.29%
1997 -25.80%
1996 133.79%
1995 86.60%
1994 -25.42%
1993 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$527.89 35.09%
US
$996.61 51.72%
NL
$116.54 -19.94%
AU
$735.86 6.07%
CH
$257.75 14.92%
BE